PharmGen Science, Inc. (KRX:004720)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,120.00
-55.00 (-1.32%)
Mar 17, 2025, 9:00 AM KST

PharmGen Science Revenue

PharmGen Science had revenue of 41.65B KRW in the quarter ending September 30, 2024, with 1.22% growth. This brings the company's revenue in the last twelve months to 173.60B, up 9.08% year-over-year. In the year 2023, PharmGen Science had annual revenue of 166.78B with 10.50% growth.

Revenue (ttm)
173.60B
Revenue Growth
+9.08%
P/S Ratio
0.42
Revenue / Employee
683.46M
Employees
254
Market Cap
72.64B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023166.78B15.85B10.50%
Dec 31, 2022150.93B41.06B37.38%
Dec 31, 2021109.87B13.25B13.72%
Dec 31, 202096.61B1.48B1.55%
Dec 31, 201995.14B6.04B6.77%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,547.32B
Celltrion 3,557.30B
ALTEOGEN 102.85B
Yuhan 2,067.79B
SK Biopharmaceuticals 547.60B
HLB Co., Ltd. 51.92B
Sam Chun Dang Pharm. 210.92B
PharmaResearch 350.12B
Revenue Rankings